Lacosamide TY - T1的耐受性和Zonisamide治疗老年癫痫患者(P5.226) JF -神经学乔-神经学六世- 88 - 16补充SP - P5.226盟约翰尼尼古拉斯AU - Jong李盟王妃Sarkis Y1 - 201首页7/04/18 UR - //www.ez-admanager.com/content/88/16_Supplement/P5.226.abstract N2 -目的:调查Lacosamide的耐受性(LCS)和Zonisamide锌矿)在癫痫的老年人口。背景:老年人癫痫的患病率是年轻人和发病率增加的两倍以更高的速度为每十年后60岁。虽然发作一般控制和适当治疗,药物的耐受性仍然是一个重大的障碍。设计/方法:回顾性图表回顾研究60岁及以上的癫痫患者治疗lacosamide或zonisamide门诊。收集的数据包括癫痫变量(癫痫持续时间、发作频率、发作符号学),伴随的药物,和医学并存病。主要结果终于保留率跟进。结果:共有84名LCS 39的硫化锌和患者确认。LCS的药物引发学生平均年龄为70.7±7.0岁,50%是医学上耐火材料,78.4%有广义强直性阵挛性的癫痫(GTC)。平均随访时间为22.6±21.2个月。最后跟进,停药率为30%,没收自由率为51%。由于副作用的21个中止,8(38%)是由于头晕/步态不稳。 The only predictor of discontinuation was the last dose. Average age at drug initiation for ZNS was 69.7 ± 6.9 years, 51% were medically refractory, and 43.6% had a history of GTCs. Average duration of follow up was 46.3 ± 38.3 months. At last follow up, the discontinuation rate was 31% and seizure freedom rate was 67%. Of the 12 discontinuations due to side effects, 3 (25%) were due to fatigue. Predictors of discontinuation included the starting dose and a history of being refractory to medications.Conclusions: Lacosamide and Zonisamide are viable options for the treatment of epilepsy in the elderly with similar retention rates.Disclosure: Dr. Nicolas has nothing to disclose. Dr. Lee has received personal compensation for activities with DigiTrace/SleepMed. Dr. Lee has received research support from NINDS, UCB, Inc, Sunovion, Lundbeck and SleepMed/DigiTrace. Dr. Sarkis has nothing to disclose. ER -